AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells
Open Access
- 19 January 2020
- Vol. 9 (1), 247
- https://doi.org/10.3390/cells9010247
Abstract
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer with high risk of relapse and metastasis. TNBC is a heterogeneous disease comprising different molecular subtypes including those with mesenchymal features. The tyrosine kinase AXL is expressed in mesenchymal cells and plays a role in drug resistance, migration and metastasis. We confirm that AXL is more expressed in mesenchymal TNBC cells compared to luminal breast cancer cells, and that its invalidation impairs cell migration while having no or little effect on cell viability. Here, we found that AXL controls directed migration. We observed that AXL displays a polarized localization at the Golgi apparatus and the leading edge of migratory mesenchymal TNBC cells. AXL co-localizes with F-actin at the front of the cells. In migratory polarized cells, the specific AXL inhibitor R428 displaces AXL and F-actin from the leading edge to a lateral area localized between the front and the rear of the cells where both are enriched in protrusions. In addition, R428 treatment disrupts the polarized localization of the Golgi apparatus towards the leading edge in migratory cells. Immunohistochemical analysis of aggressive chemo-resistant TNBC samples obtained before treatment reveals inter- and intra-tumor heterogeneity of the percentage of AXL expressing tumor cells, and a preference of these cells to be in contact with the stroma. Taken together, our study demonstrates that AXL controls directed cell migration most likely by regulating cell polarity.This publication has 77 references indexed in Scilit:
- Molecular stratification within triple-negative breast cancer subtypesScientific Reports, 2019
- Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seqNature Communications, 2018
- The Epithelial-to-Mesenchymal Transition in Breast Cancer: Focus on Basal-Like CarcinomasCancers, 2017
- Intratumor heterogeneity predicts metastasis of triple-negative breast cancerCarcinogenesis: Integrative Cancer Research, 2017
- Triple negative breast cancer: the kiss of deathOncotarget, 2017
- Molecular alterations in triple-negative breast cancer—the road to new treatment strategiesThe Lancet, 2016
- Targeted therapy for breast cancer and molecular mechanisms of resistance to treatmentCurrent Opinion in Pharmacology, 2016
- Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy SelectionPLOS ONE, 2016
- Molecular Classification of Triple-Negative Breast CancerJournal of Breast Cancer, 2016
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJCI Insight, 2011